您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2010, Vol. 48 ›› Issue (4): 36-.

• 论文 • 上一篇    下一篇

辛伐他汀对COPD大鼠模型炎症的干预作用

陈旭东,王伟,王永彬   

  1. 山东大学第二医院呼吸科, 济南   250033
  • 收稿日期:2009-11-24 出版日期:2010-04-16 发布日期:2010-04-16
  • 通讯作者: 王伟(1963- ),男,主任医师,硕导,主要从事慢性阻塞性肺疾病的诊断和治疗。 Email:ww8160@163.com
  • 作者简介:陈旭东(1983- ),男,硕士研究生,主要从事慢性阻塞性肺疾病的诊断和治疗。 E-mail:chenxudong8312@163.com
  • 基金资助:

    山东省自然科学基金资助项目(Y2008C19)。

Effect of simvastatin on inflimmation in chronic obstructive  pulmonary disease rat model

CHEN Xudong, WANG Wei, WANG Yongbin   

  1. Department of Respiratory, The Second Hospital of Shandong University, Jinan 250033, China
  • Received:2009-11-24 Online:2010-04-16 Published:2010-04-16

摘要:

目的  观察辛伐他汀对慢性阻塞性肺疾病(COPD)大鼠模型炎症因子及其肺组织病理的影响,探讨辛伐他汀在COPD治疗中的抗炎作用及其机制。方法  采用熏香烟加气管内滴入LPS法建立大鼠COPD模型,随机将30只雄性Wistar大鼠分为正常对照组、COPD模型组和辛伐他汀治疗组,治疗组在造模两周后给予辛伐他汀2.5mg/kg灌胃治疗,每天1次,治疗6周后,观察各组大鼠的体质量增长率,肺组织的病理改变,行支气管肺泡灌洗液(BALF)细胞计数和分类,先分别测定BALF和血清中IL-8及TNF-α的水平、再测定血清中C-反应蛋白(CRP)的水平。结果  治疗组较模型组体质量增长率显著提高(P<0.05);模型组大鼠出现明显慢性支气管炎特征性病理改变,出现肺气肿,气管及血管周围大量炎症细胞浸润,治疗组也出现肺气肿和炎症浸润,但程度较模型组轻;治疗组BALF细胞总数和中性粒细胞比例较模型组均有显著下降(P<0.05);治疗组 BALF及血清中IL-8 、TNF-α、CRP水平均较模型组显著降低(P<0.05)。结论  辛伐他汀可降低COPD大鼠模型BALF和血清中的炎症因子,减轻肺组织及气道炎症,对COPD大鼠的炎症有抑制作用。

关键词: 肺疾病,慢性阻塞性;炎症;大鼠,Wistar;辛伐他汀

Abstract:

Objective  To observe the effect of simvastatin on inflammatory factors and lung pathology of the chronic obstructive pulmonary disease (COPD) rat model, and to investigate the therapeutic action of simvastatin on COPD. Methods  The COPD rat model was established by intratracheal instillation of lipopolysaccharide twice and exposure to daily cigarette. 30 male Wistar rats were randomly divided into three groups: the normal control group, the COPD model group and simvastatintreated group. The simvastatin treated group was treated with  2.5mg/kg simvastatin daily from the end of the second week for 6 weeks. The weight growth of each group, and total and differential cell counts in bronchoalveolar lavage fluid (BALF) were observed and  the pathomorphological changes in the lung were analyzed. IL-8 and TNF-α levels in BALF and serum, and CRP level in the serum were determined. Results  The weight growth rate of the simvastatin treated group was significantly higher than that of the COPD model group(P<0.05). Pathological changes of COPD were observed in the COPD rat model. Airway inflammation was significantly increased in the COPD model group and emphysema was observed, which also appeared in the simvastatin treated group to a lighter degree. The total inflammatory cells and the proportion of neutrophils in BALF increased in the COPD model group compared with  the normal control group, while they were  significantly decreased in the simvastatin treated group(P<0.05). IL-8 and TNF-α levels in BALF and serum were more significantly decreased  in the simvastatin treated group than in the COPD model group (P<0.05), and CRP level in the serum also decreased in the simvastatin treated group (P<0.05). Conclusion  Simvastatin can reduce inflammatory factors in BALF and the serum of the COPD rat model and decrease  inflammation of the lung tissue and airway. So simvastatin can inhibit the inflammation of the COPD rat model.

Key words: Pulmonary disease, chronic obstructive; Inflammation; Rats, Wistar; Simvastatin

中图分类号: 

  • R563.3
[1] 丁启翠1,王伟1,王永彬1,陈旭东2,吴倩1. 辛伐他汀对COPD大鼠肺组织凋亡相关因子的影响[J]. 山东大学学报(医学版), 2012, 50(6): 65-.
[2] . SERPINE2基因多态性与慢性阻塞性肺疾病的相关性[J]. 山东大学学报(医学版), 2009, 47(7): 111-114.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!